Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Ovarian Cancer Metastatic × aldesleukin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 123 Carcinoma, Renal Cell 47 Kidney Neoplasms 38 Neoplasm Metastasis 35 Leukemia, Myeloid, Acute 33 Leukemia 32 Lymphoma 30 Breast Neoplasms 22 Lymphoma, Non-Hodgkin 21 Ovarian Neoplasms 20 Skin Neoplasms 19 Precursor Cell Lymphoblastic Leukemia-Lymphoma 18 Lymphoma, Follicular 17 Carcinoma, Non-Small-Cell Lung 17 Neuroblastoma 16 Lymphoma, Mantle-Cell 15 Leukemia, Lymphocytic, Chronic, B-Cell 15 Pancreatic Neoplasms 14 Stomach Neoplasms 13 Neoplasms 13 Myelodysplastic Syndromes 13 Lymphoma, Large B-Cell, Diffuse 12 Multiple Myeloma 11 Lymphoma, Large-Cell, Immunoblastic 11 Lymphoma, B-Cell, Marginal Zone 11 Hodgkin Disease 11 Burkitt Lymphoma 11 Recurrence 10 Colorectal Neoplasms 10 Uterine Cervical Neoplasms 9

Interventions

fludarabine 1 aldesleukin 1 Interleukin-2 1 Cyclophosphamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04389229 2020-12-16

OVSTAR

Immetacyte Ltd

Phase 1/2 Withdrawn

Ovarian Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡